Patheon to Highlight Sterile and Biologic Capabilities at PDA Annual Meeting

Patheon , the pharmaceutical services business owned by DPx Holdings, will showcase the company’s sterile drug product capabilities and biologic drug substance offerings at the PDA Annual Meeting in San Antonio, Texas, April 7-9, 2014.

The biologic drug substance capabilities is a new offering to compliment already existing sterile fill/finish capabilities available from Patheon. With the addition of the two state-of-the-art cGMP drug substance facilities located in the Netherlands and Australia, Patheon is now able to provide world class mammalian process development and cGMP manufacturing services, from pre-clinical to commercial supply, to its global client base.

Warren Horton, vice president of Quality and Regulatory Affairs, as part of the Sterile Product Manufacturing concurrent session, will present as part of the PDA , “CMOs and Quality Agreements: Contract Manufacturing and Testing,” on Monday, April 7 at 11:15 a.m.

In addition, many executives from Patheon as well as technical and scientific experts will attend the PDA Annual Meeting and will be available to discuss the full complement of sterile  fill/finish capabilities and biologic drug substance offerings. Representatives can be found in Booth #309 for the duration of the conference. To schedule a meeting in advance, please email events@patheon.com .

The theme of this year’s PDA Annual Meeting is “Biopharmaceutical and Sterile Pharmaceutical Manufacturing – Embracing Innovation to Meet Global Challenges.”

For more information on upcoming events, visit http://www.patheon.com/Knowledge-Library/Events.aspx .

Patheon 

Tel: +1 (919) 226-3200

Email: media@patheon.com   

Patheon is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Patheon, a DPX business unit, encompasses the combined CMO capabilities and pharmaceutical product development services (PDS), as well as the Biosolutions and Biologics (BIO) business. For more information visit http://www.patheon.com .

About Us

Patheon® is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms, including large and small molecule API. Patheon, a business unit of DPx Holdings B.V., encompasses the combined commercial manufacturing capabilities and pharmaceutical product development services, as well as offers a full array of biologic services and pharmaceutical active pharmaceutical ingredients (API) development. Patheon is #1 in product development services, #2 in commercial scale product manufacturing and is #1 in quality. For more information, visit http://www.patheon.com.